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Phenotype–genotype complexities: opening DOORS
The escalating pace of molecular genetic discoveries in 
neurological diseases is repeatedly providing surprises 
that challenge our ability to match phenotype and 
genotype. With the current transition of whole-exome 
sequencing from the laboratory to clinical use, the 
ability to understand and interpret molecular-level data 
becomes ever more important.1 The classic view of one 
gene encoding one protein, with disruption resulting in 
one disease, is rooted in Archibald Garrod’s remarkable 
insights into inborn errors of metabolism more than 
100 years ago. This simplistic view now seems to be in 
doubt for many genes. 
In The Lancet Neurology, Philippe Campeau and 
colleagues2 show that, in about half of aﬀ ected people 
from the 26 families studied, DOORS syndrome is 
due to a mutation in the gene TBC1D24. DOORS, 
a rare autosomal recessive disorder, gets its name 
from an acronym of its ﬁ ve main features—deafness, 
onychodystrophy, osteodystrophy, mental retardation, 
and seizures.3,4  Campeau and colleagues’ ﬁ ndings2 draw 
attention to several important issues. 
First, with the widespread availability of whole-exome 
sequencing technology, novel ﬁ ndings, or discoveries, 
are now easier to come accross, even in small series 
or single case studies. Some of these ﬁ ndings might 
be false positives, but in Campeau and colleagues’ 
report, robust inferences about the genetics of DOORS 
syndrome can be made because the investigators 
identiﬁ ed TBC1D24 mutations in a large proportion 
of aﬀ ected individuals in a unique, large international 
cohort of patients with this rare disorder. 
Second, even rare, distinctive, and multisystem 
disorders can be genetically heterogeneous. In Campeau 
and colleagues’ study,2 18 families had individuals with 
all ﬁ ve main features of DOORS—in only nine of these 
families was the TBC1D24 mutation detected, leaving 
17 families (including the eight who had an individual 
with fewer than ﬁ ve features) with the cause for 
their DOORS undetermined. Genetic heterogeneity is 
emerging as the rule in many neurological disorders that 
seem otherwise clinically homogeneous.
Third, pleiotropy, in which the same or diﬀ erent 
mutations in a gene can have diﬀ erent clinical mani-
festations, provides a big challenge to under standing 
mechanisms and to the use of exome-sequence data 
in diagnosis and prognosis.5 Recessive mutations of 
TBC1D24 not only aﬀ ect normal development of nails, 
bone, and brain in DOORS syndrome, but also cause 
a large array of other neurological phenotypes. These 
phenotypes include mild infantile-onset myoclonic 
epilepsy with normal intellect and neuroimaging,6 a 
more severe syndrome with focal epilepsy, cognitive 
impairment, and cerebro-cerebellar malformations,7,8 a 
severe infantile-onset myoclonic epilepsy with dementia, 
progressive cerebral atrophy and childhood death,9 
and epilepsy in infancy with migrating focal seizures.10 
In these other TBC1D24-associated syndromes, the 
investigators did not detect deafness or bone or nail 
abnormalities. Epilepsy in infancy with migrating focal 
seizures is more often due to mutation of the potassium 
channel gene KCNT1,11 another example of genetic 
heterogeneity. 
The molecular function of TBC1D24 protein has 
begun to emerge over the past 4 years. Our group7 and 
Falace and colleagues,6 using diﬀ erent in-vitro assays, 
have shown that overexpression of TBC1D24 protein 
in primary mouse neurons directly aﬀ ects neurite 
length and branching6,7 as well as axonal arborisation 
and speciﬁ cation.7 TBC1D24 interacts with Arf6, one 
of a Ras-related family of small GTPases,6 which, 
among other functions, is involved in the regulation of 
exocytosis and endocytosis dynamics and neuronal cell 
polarity,12 providing an attractive molecular mechanism 
for the seizures and intellectual disability seen in most 
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The decision of what to do with asymptomatic 
unruptured intracranial aneurysms is a fairly new 
problem. Although these aneurysms have been known 
to exist for centuries through autopsies and for several 
decades through catheter angiography, their true 
prevalence did not begin to emerge until the use of 
non-invasive angiograms became widespread in the 
recent past. Now we know that nearly 3% of the general 
population has an unruptured intracranial aneurysm.1 
Comparatively, subarachnoid haemorrhages from 
aneurysmal rupture are relatively uncommon. This 
discrepancy indicates that many intracranial aneurysms 
are not destined to rupture. Yet, the consequences of 
rupture can be devastating.2 Treatment of the aneurysm 
by craniotomy and clipping or by endovascular coiling 
can eﬀ ectively eliminate the risk of subarachnoid 
haemorrhages, but treatment of all unruptured 
intracranial aneurysms is neither prudent, because of 
the risk of iatrogenic complications, nor parsimonious, 
because of the high ﬁ nancial cost.3 Thus, when advising 
a patient with an asymptomatic unruptured intracranial 
aneurysm we face a diﬃ  cult problem. An adequate 
solution can only be based on individualisation of the 
rupture risk.
In The Lancet Neurology, Jacoba Greving and 
colleagues4 present their analysis of individual patient 
data pooled from six prospective cohort studies on the 
natural history of unruptured intracranial aneurysms 
(three from Japan, one from the Netherlands, one 
from Finland, and one from the USA, Canada, and 
TBC1D24-associated phenotypes, including DOORS. 
Campeau and colleagues2 also show that the crucial 
function of TBC1D24 extends beyond neuronal cells, 
to chondrocytes and bone. Why only some TBC1D24 
mutations are associated with a chondrocyte and bone 
phenotype is unknown. 
The underlying cellular and molecular mechanism 
for the growing number of TBC1D24-associated 
phenotypes is far from clear. Whether the explanation 
is in the TBC1D24 mutations themselves, TBC1D24-
associated proteins and pathways, or precise timing 
of TBC1D24 function during development has not 
been established. The framework for understanding 
phenotype–genotype correlation is more complicated 
than was envisaged by Garrod and his early successors. 
Elucidation of this association will be crucial for deeper 
understanding in the laboratory and the clinic, and for 
the development of new treatments.  In view of what 
is known so far about TBC1D24-mutation pleiotropy, 
studies such as that of Campeau and colleagues2 will 
provide new opportunities toward achieving this goal. 
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